Category: Wegovy
-
Zepbound (tirzepatide) superior to Wegovy (semaglutide), says Lilly-funded clinical trial
•
In the midst of the war on obesity, a clear winner has emerged in the battle between two weight-loss injections. Zepbound (tirzepatide), made by Fortune 500 company Eli Lilly & Co., outperformed competitor Wegovy (semaglutide), a Novo Nordisk Top 500 product, in a recent study Randomized clinical trial Supported by…
-
Medicare coverage of Novo Nordisk’s Wegovy could cost up to $145B annually
•
aprott/iStock via Getty Images Novo Nordisk’s (NVO) weight-loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries with obesity and cardiovascular disease, could cost the system up to $145 billion a year. If all eligible beneficiaries receive Wegovy If achieved, it would cost Medicare between $34 billion and $145…
-
Novo’s Wegovy induces higher weight loss in women than men with same heart condition, study shows By Reuters
•
Written by Jakob Gronholt Pedersen and Bhanvi Satya COPENHAGEN (Reuters) – An analysis of data from a study published in a medical journal showed that Novo Nordisk Inc’s (NYSE) popular obesity drug WiGovi helped women with common heart diseases lose more weight than men with the same condition. The trials…
-
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy By Reuters
•
(Reuters) – Novo Nordisk (NYSE:) CEO Lars Jorgensen has agreed to voluntarily testify at a hearing focusing on U.S. prices for weight-loss drugs Ozempic and Wegovy, the Senate Committee on Health, Education, Labor and Pensions said on Friday. A vote by the US Senate Health Committee, which was scheduled to…
-
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices By Reuters
•
WASHINGTON (Reuters) – The U.S. Senate Health Committee said on Tuesday it will vote this month on whether to subpoena Novo Nordisk (NYSE:) to answer questions about U.S. prices for weight-loss drugs Ozempic and Wegovy, which are much higher than their prices in other countries. . countries. The Senate Committee…
-
Hims 85% Wegovy and Ozempic discount is latest step on a journey to make medicine less ‘paternalistic,’ exec says
•
Traditional medical practices are getting a boost from new entrants seeking to fill gaps in what health industry executives described Monday as an underdeveloped health care system. That includes Hims & Hers, a direct-to-consumer health company that announced Monday that it will launch a combination version of its weight-loss drugs…
-
Denmark’s Novo Nordisk expects 27% sales surge this year but faces price pressure for weight loss drug Wegovy amid Eli Lilly competition
•
Novo Nordisk A/S raised its earnings forecast as the drugmaker now ships five times more introductory doses of the weight-loss drug Wegovy in the US than at the end of last year. More than 25,000 patients are now starting treatment each week in the United States, CEO Lars Frørgaard Jørgensen…